Semaglutide is a weight loss drug that targets the glucagon-like peptide-1 (GLP-1), sold by Novo Nordisk under the brand name Wegovy to treat people with obesity and under Ozempic to treat patients with both type 2 diabetes and obesity
[3] Some preclinical studies suggest GLP-1 may have beneficial effects on pancreatic beta cells, though long-term preservation of function in humans remains unproven
Our bodies produce it naturally in the liver and kidneys, and store it in muscles, sperm, brain, and the heart
Industry organizations such as the Alliance for Peptide Professionals are collaborating with regulators to establish safety, purity, and documentation standards for clinical-grade use
This is not only a problem for young children
As more patients like Chelsea try out microdosing, we went to the experts: is it legit